Charlotte Erica Victoria Andersson, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebrovascular Trauma | 1 | 2015 | 21 | 0.490 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2015 | 198 | 0.440 |
Why?
|
| Kidney Failure, Chronic | 1 | 2023 | 2495 | 0.360 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 4 | 2008 | 452 | 0.350 |
Why?
|
| Heart Failure | 4 | 2023 | 11840 | 0.350 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 870 | 0.330 |
Why?
|
| Stroke | 3 | 2023 | 9747 | 0.310 |
Why?
|
| Kidney Transplantation | 1 | 2023 | 4270 | 0.300 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2007 | 61 | 0.280 |
Why?
|
| Docosahexaenoic Acids | 4 | 2008 | 916 | 0.270 |
Why?
|
| Cystic Fibrosis | 5 | 2008 | 1287 | 0.270 |
Why?
|
| Macrophages, Peritoneal | 1 | 2007 | 243 | 0.270 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 2817 | 0.250 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2007 | 852 | 0.250 |
Why?
|
| Myocardial Infarction | 3 | 2023 | 11499 | 0.230 |
Why?
|
| Cardiovascular Diseases | 3 | 2023 | 15652 | 0.220 |
Why?
|
| Coronary Artery Disease | 1 | 2022 | 6544 | 0.200 |
Why?
|
| Overweight | 1 | 2013 | 2444 | 0.200 |
Why?
|
| Fatty Acids | 3 | 2010 | 1806 | 0.190 |
Why?
|
| Cognition Disorders | 1 | 2015 | 3967 | 0.180 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 3110 | 0.180 |
Why?
|
| Linoleic Acid | 3 | 2008 | 157 | 0.150 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2021 | 855 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2007 | 3081 | 0.120 |
Why?
|
| PPAR alpha | 2 | 2006 | 175 | 0.120 |
Why?
|
| Fatty Liver | 3 | 2006 | 807 | 0.120 |
Why?
|
| Gallstones | 1 | 2016 | 285 | 0.110 |
Why?
|
| Cyclobutanes | 1 | 2013 | 57 | 0.110 |
Why?
|
| Coronary Artery Bypass | 1 | 2022 | 2186 | 0.110 |
Why?
|
| Sulfonylurea Compounds | 1 | 2013 | 221 | 0.100 |
Why?
|
| Metabolomics | 1 | 2021 | 1668 | 0.090 |
Why?
|
| Obesity | 1 | 2013 | 13076 | 0.090 |
Why?
|
| Coronary Angiography | 1 | 2022 | 4493 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 9601 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 12240 | 0.080 |
Why?
|
| Phospholipids | 3 | 2010 | 776 | 0.080 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2010 | 304 | 0.080 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2008 | 37 | 0.080 |
Why?
|
| Brain | 1 | 2015 | 27171 | 0.080 |
Why?
|
| Fish Oils | 2 | 2010 | 483 | 0.070 |
Why?
|
| Fatty Acids, Essential | 1 | 2008 | 97 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2013 | 1441 | 0.070 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2007 | 63 | 0.070 |
Why?
|
| Middle Aged | 7 | 2023 | 223009 | 0.070 |
Why?
|
| Genetic Loci | 1 | 2016 | 2631 | 0.070 |
Why?
|
| Risk | 2 | 2021 | 9591 | 0.070 |
Why?
|
| Coronary Disease | 1 | 2021 | 5912 | 0.070 |
Why?
|
| Growth | 1 | 2008 | 365 | 0.060 |
Why?
|
| Culture Media | 1 | 2008 | 890 | 0.060 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2009 | 314 | 0.060 |
Why?
|
| Metformin | 1 | 2013 | 904 | 0.060 |
Why?
|
| Organelles | 1 | 2007 | 264 | 0.060 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2005 | 1396 | 0.060 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2006 | 226 | 0.060 |
Why?
|
| Spectrum Analysis | 1 | 2007 | 443 | 0.060 |
Why?
|
| Bile Ducts | 1 | 2006 | 288 | 0.060 |
Why?
|
| Male | 10 | 2023 | 363698 | 0.060 |
Why?
|
| Bronchi | 1 | 2008 | 843 | 0.060 |
Why?
|
| Cell Count | 1 | 2008 | 1823 | 0.060 |
Why?
|
| Aged | 6 | 2022 | 171117 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2009 | 622 | 0.050 |
Why?
|
| Hydroxamic Acids | 1 | 2006 | 483 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 14751 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2006 | 538 | 0.050 |
Why?
|
| Female | 7 | 2023 | 396112 | 0.050 |
Why?
|
| Aortic Valve Stenosis | 1 | 2015 | 2023 | 0.050 |
Why?
|
| Microscopy | 1 | 2007 | 901 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2010 | 2002 | 0.050 |
Why?
|
| Dietary Carbohydrates | 1 | 2006 | 894 | 0.050 |
Why?
|
| Homoarginine | 1 | 2021 | 9 | 0.050 |
Why?
|
| Orotic Acid | 1 | 2021 | 24 | 0.050 |
Why?
|
| Spermine | 1 | 2021 | 70 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 1966 | 0.050 |
Why?
|
| Uridine | 1 | 2021 | 135 | 0.040 |
Why?
|
| Living Donors | 1 | 2005 | 645 | 0.040 |
Why?
|
| Polyamines | 1 | 2021 | 130 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 2216 | 0.040 |
Why?
|
| Humans | 12 | 2023 | 765968 | 0.040 |
Why?
|
| Pancreas | 1 | 2006 | 1700 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 59489 | 0.040 |
Why?
|
| Proline | 1 | 2021 | 453 | 0.040 |
Why?
|
| Insulin | 1 | 2013 | 6599 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2007 | 18293 | 0.040 |
Why?
|
| Mice | 9 | 2008 | 81819 | 0.040 |
Why?
|
| Liver | 3 | 2010 | 7562 | 0.040 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2021 | 394 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2008 | 18973 | 0.040 |
Why?
|
| Glucose | 1 | 2010 | 4335 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 2 | 2010 | 415 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2009 | 3141 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2007 | 14448 | 0.030 |
Why?
|
| Triglycerides | 3 | 2010 | 2441 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2022 | 65188 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2007 | 2858 | 0.030 |
Why?
|
| Risk Factors | 1 | 2023 | 74840 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2006 | 3222 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2008 | 3681 | 0.030 |
Why?
|
| Animals | 11 | 2010 | 168764 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 18071 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 26318 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2007 | 2932 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2005 | 2412 | 0.030 |
Why?
|
| Population Dynamics | 1 | 2015 | 314 | 0.030 |
Why?
|
| Collagen | 1 | 2021 | 2618 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2021 | 2143 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2005 | 3425 | 0.020 |
Why?
|
| Sweden | 1 | 2015 | 1381 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2021 | 22223 | 0.020 |
Why?
|
| Inflammation | 1 | 2010 | 10850 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2015 | 2263 | 0.020 |
Why?
|
| Incidence | 2 | 2021 | 21480 | 0.020 |
Why?
|
| Morbidity | 1 | 2015 | 1749 | 0.020 |
Why?
|
| Age Distribution | 1 | 2015 | 2858 | 0.020 |
Why?
|
| Malondialdehyde | 1 | 2009 | 112 | 0.020 |
Why?
|
| Soybean Oil | 1 | 2010 | 139 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 3047 | 0.020 |
Why?
|
| Drug Stability | 1 | 2009 | 288 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2010 | 8102 | 0.020 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2008 | 65 | 0.020 |
Why?
|
| Lipogenesis | 1 | 2010 | 217 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 4562 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 36532 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 4 | 2008 | 22332 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 1892 | 0.020 |
Why?
|
| C-Reactive Protein | 2 | 2010 | 3850 | 0.020 |
Why?
|
| Caloric Restriction | 1 | 2010 | 304 | 0.020 |
Why?
|
| Mice, Inbred CFTR | 1 | 2006 | 18 | 0.020 |
Why?
|
| Cholesterol | 1 | 2016 | 2898 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 562 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2021 | 5596 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2008 | 430 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 12509 | 0.020 |
Why?
|
| Scattering, Radiation | 1 | 2007 | 482 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 2006 | 255 | 0.010 |
Why?
|
| Respiratory Mucosa | 1 | 2008 | 438 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2004 | 12131 | 0.010 |
Why?
|
| Equipment Failure Analysis | 1 | 2007 | 834 | 0.010 |
Why?
|
| Random Allocation | 1 | 2009 | 2395 | 0.010 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2015 | 1566 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2007 | 23601 | 0.010 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2008 | 565 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2016 | 9649 | 0.010 |
Why?
|
| Mortality | 1 | 2015 | 2904 | 0.010 |
Why?
|
| Rats | 2 | 2010 | 23707 | 0.010 |
Why?
|
| PPAR gamma | 1 | 2006 | 483 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 1526 | 0.010 |
Why?
|
| Models, Animal | 1 | 2009 | 2120 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13266 | 0.010 |
Why?
|
| Thiazolidinediones | 1 | 2004 | 459 | 0.010 |
Why?
|
| Energy Intake | 1 | 2008 | 2141 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2009 | 6203 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2006 | 12768 | 0.010 |
Why?
|
| Equipment Design | 1 | 2007 | 3481 | 0.010 |
Why?
|
| Adult | 3 | 2021 | 223044 | 0.010 |
Why?
|
| Registries | 1 | 2015 | 8297 | 0.010 |
Why?
|
| Phenotype | 1 | 2016 | 16721 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 5747 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 2927 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 5020 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 12807 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 16047 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2007 | 5302 | 0.010 |
Why?
|
| Lipids | 1 | 2006 | 3315 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 2080 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 4348 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 10729 | 0.010 |
Why?
|
| Prognosis | 1 | 2015 | 29922 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 15543 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 9550 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2004 | 3046 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2015 | 15747 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 14652 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 11022 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 20124 | 0.000 |
Why?
|
| Young Adult | 1 | 2015 | 59889 | 0.000 |
Why?
|
| Diet | 1 | 2005 | 8086 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 11888 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2015 | 81514 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2009 | 54802 | 0.000 |
Why?
|
| Mutation | 1 | 2006 | 30198 | 0.000 |
Why?
|